[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"varicella\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:varicella":56},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,115,138,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":84,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":114},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537",false,"NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.",true,"ALL","2 Years","75 Years",{"count":21,"type":22},10000,"ESTIMATED","OBSERVATIONAL","RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis",[85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","RECRUITING","2026-01-14",{"date":105,"type":106},"2026-01-22","ACTUAL",{"date":108,"type":106},"2025-12-18",{"date":110,"type":22},"2027-09-30",{"name":112,"class":113},"Institut Pasteur du Cambodge","OTHER",1,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":16,"sex":17,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100553140","correlation-of-protection-against-varicella-in-an-exploratory-study-100553140","NCT06482216","Correlation of Protection Against Varicella in an Exploratory Study","Inclusion Criteria:\n\n* 1-12 years children who were the siblings or children of the indicator varicella cases, or the deskmates\u002Froommates of the indicator varicella cases;\n* Having close contacts with the indicator varicella cases at least 2 days during the period from 5 days before the onset and 2 days after the onset;\n* Without varicella vaccination history or having varicella vaccination history (the last dose of varicella was manufacured by Sinovac, with an interval of \\>30 days before enrollment)\n* Subjects\u002Flegal guardian can understand and sign the informed consent;\n* Being able to provide legal proof of identity.\n\nExclusion Criteria:\n\n* Without varicella history;\n* Body temperature ≥37.0℃ on the day of enrollment, or skin rash on the head, torso, and limbs;\n* Having any confirmed or suspected immunodeficiency disorder, including tumor patients undergoing chemotherapy, human immunodeficiency virus (HIV) infection, continuous use of steroid hormones for more than 30 days (prednisone equivalent ≥2mg\u002Fkg days in children), or having other immunosuppressive disorder as determined by the clinician;\n* The investigators considered that participation in this study was not appropriate for various other reasons.","1 Year","12 Years",{"count":124,"type":22},400,"This study consists of two parts. Part 1 is a retrospective cohort study and part 2 is a prospective cohort study. In Part 1 ,the scaled logit model was used to assess the correlation between varicella-zoster virus (VZV) antibody titers using fluorescent-antibody-to-membrane-antigen assay (FAMA) 30 days after varicella vaccine immunization and the risk of subsequent varicella breakout\u002Fdisease , to determine the protective threshold for achieving FAMA antibodies. Part 2 was to validate the model in part 1.",[56],"NOT_YET_RECRUITING","2025-01-23",{"date":130,"type":106},"2025-01-27",{"date":132,"type":22},"2025-10-10",{"date":134,"type":22},"2028-10-10",{"name":136,"class":137},"Sinovac (Dalian) Vaccine Technology Co., Ltd.","INDUSTRY",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":150,"studyType":23,"phases":4,"briefSummary":151,"conditions":152,"keywords":159,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":114},"100398696","pediatric-and-ambulatory-research-in-infectious-diseases-100398696","NCT04471493","Pediatric and Ambulatory Research in Infectious Diseases","Real Time Surveillance of Pediatric Infectious Diseases in French Ambulatory Care: PARI Study","PARI","Inclusion Criteria:\n\n* Children under 16 years of age with at least one infectious disease among:\n* pharyngitis\n* otitis\n* pneumonia\n* influenza\n* bronchiolitisz\n* varicella\n* gastroenteritis\n* enterovirus disease\n* bordetella pertussis disease\n* using the same same software, Axi5-Infansoft (developed by CompuGroup Medical, Nanterre, France)\n\nExclusion Criteria:\n\n* parental refusal","1 Day","16 Years",{"count":149,"type":22},400000,"5 Years","Many ambulatory networks are mainly based on diagnoses made by first-line physicians not specifically trained to join the network. Here we aim to set up a surveillance network on pediatric infectious diseases with an investment in teaching with specific trainings of participating pediatricians, increasing in use of point of care tests, and automated data extraction from the computers of the pediatricians.",[153,154,155,156,56,157,158],"Otitis","Bronchiolitis","Influenza","Pharyngitis","Pneumonia","Gastroenteritis",[160,161,162,163,164],"Vaccination","Antibiotic treatment","Point of care test","automated data extraction","network","2024-02-07",{"date":167,"type":106},"2024-02-08",{"date":169,"type":106},"2017-06-26",{"date":171,"type":22},"2030-08-02",{"name":173,"class":113},"Association Clinique Thérapeutique Infantile du val de Marne",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":16,"sex":17,"minAge":181,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":185,"phases":186,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":114},"100471717","phase-2-evaluate-the-safety-and-immunogenicity-after-mg1111baricela-inj-as-2nd-vaccination-in-4--6-year-old-healthy-children-with-a-history-of-1st-varicella-vaccination-100471717","NCT05422508","Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination","A Double-blind, Randomized, Multi-Center, Active Controlled Phase 2 Clinical Trial to Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination","Inclusion Criteria:\n\n* Healthy children between 4 and 6 years of age as of the date of written consent\n* Subjects who have a history of 1st Varicella vaccination at least 3 years ago from the administration of investigational product\n* Subjects or parent\u002Flegal representative willing to provide written informed consent and able to comply with the study requirements\n* Negative history of Varicella infection\n\nExclusion Criteria:\n\n* Subjects with a history of exposure to varicella through contact with a varicella patient at home, school, or childcare facility within 4 weeks before the administration of investigational drug\n* Subjects who have a history 2 times or more of varicella vaccine injections\n* Subjects who had an acute febrile (at least 38.0 ℃) episode at some time during the 72 hours before the administration of investigational product\n* Subjects who had any suspected allergy symptoms including systemic rash during the 72 hours before the administration of investigational product\n* Subjects with a history of Guillain-Barre syndrome.\n* Subjects with a severe chronic disease and considered ineligible for the study at Investigator's discretion\n* Subjects with a history of hypersensitivity to any ingredient such as gelatin, antibiotics (Neomycin, Kanamycin, Erythromycin)\n* Active tuberculosis patient\n* Subjects who had received other vaccinations within 4 weeks before the administration of investigational product\n* Subjects with immunodeficiency history\n* Subjects who had received salicylates (aspirin, bismuth, subsalicylates) within 4 weeks before the administration of investigational drug\n* Subjects who administered immune globulin, gamma globulin, or blood products such as whole blood within 44 weeks before the administration of investigational drug\n* Subjects who had received immunosuppressant or immune modifying drug within 12 weeks before the administration of investigational drug\n* A. Azathioprine, Cyclosporin, Interferon, G-CSF, Tacrolimus, Everolimus, Sirolimus, etc.\n* B. Subjects who administered high dose of corticosteroids (greater than 2 mg\u002Fkg\u002Fday in case of under 10kg subjects or ≥20mg\u002Fday in case of above 10kg subject of prednisone for 14 days) (However, inhaled, intranasal, topical corticosteroids administration in allowed)\n* Subjects who administered anti-viral drug within 4 weeks before the administration of investigational drug\n* Subjects who have participated in any other clinical trials within 24 weeks of the administration of the investigational product\n* Subjects with other clinically significant medical or psychological condition who are considered by the Investigator to be ineligible for the study","4 Years","6 Years",{"count":184,"type":22},230,"INTERVENTIONAL",[187],"PHASE2","* Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination\n* Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination",[56],"2024-01-23",{"date":192,"type":106},"2024-01-24",{"date":194,"type":106},"2022-07-05",{"date":196,"type":22},"2027-06",{"name":198,"class":137},"Green Cross Corporation"]